By Michael Susin
Centessa Pharmaceuticals shares rose Tuesday after the company said it planned to advance its narcolepsy drug to a phase 2 trial following encouraging early study data.
In the premarket trading, shares were up 15% at $17.15. The share price has more than doubled over the past 52 weeks.
The British pharmaceutical company said interim data from a continuing phase 1 study showed its drug ORX750 restored wakefulness in acutely sleep-deprived patients.
It added the drug showed meaningful and significant improvements in mean sleep latency--the time it takes to fall asleep--at the first two doses evaluated in the maintenance-of-wakefulness test compared to placebo, along with a favorable safety profile.
The company said it plans to rapidly advance ORX750 into phase 2 study in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
The mid-stage trial is expected to start in the fourth quarter of 2024.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 10, 2024 08:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.